Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St Johns University, Queens, NY 11439, USA.
Microbes Infect. 2010 Dec;12(14-15):1198-207. doi: 10.1016/j.micinf.2010.08.006. Epub 2010 Aug 26.
Human cerebral malaria causes neurological and behavioral deficits which persist long after resolution of infection and clearance of parasites with antimalarial drugs. Previously, we demonstrated that during active infection, mice with cerebral malaria demonstrated negative behavioral outcomes. Here we used a chloroquine treatment model of cerebral malaria to determine whether these abnormal outcomes would be persistent in the mouse model. C57BL/6 mice were infected with Plasmodium berghei ANKA, and treated for ten days. After cessation of chloroquine, a comprehensive assessment of cognitive and motor function demonstrated persistence of abnormal behavioral outcomes, 10 days after successful eradication of parasites. Furthermore, these deficits were still evident forty days after cessation of chloroquine, indicating persistence long after successful treatment, a hallmark feature of human cerebral malaria. Thus, cognitive tests similar to those used in these mouse studies could facilitate the development of adjunctive therapies that can ameliorate adverse neurological outcomes in human cerebral malaria.
人类脑型疟疾会导致神经和行为缺陷，即使在感染得到解决和抗疟药物清除寄生虫后，这些缺陷仍会持续存在。此前，我们证明了在活动性感染期间，患有脑型疟疾的小鼠会出现负面的行为结果。在这里，我们使用氯喹治疗脑型疟疾模型来确定这些异常结果是否会在小鼠模型中持续存在。用伯氏疟原虫 ANKA 感染 C57BL/6 小鼠，并治疗十天。停止氯喹治疗后，全面评估认知和运动功能显示，在成功清除寄生虫 10 天后，仍存在异常行为结果。此外，停止氯喹四十天后，这些缺陷仍然明显，表明在成功治疗后持续存在，这是人类脑型疟疾的一个显著特征。因此，类似于这些小鼠研究中使用的认知测试，可以促进辅助治疗的发展，从而改善人类脑型疟疾的不良神经结局。
